# BIO-RAD LABORATORIES, INC. (BIO) FY2026 YTD Q2 P&L / Income Statement

- Company: BIO-RAD LABORATORIES, INC. (BIO)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-04, accession number 0000012208-26-000048
- Page: https://plicit.ai/financials/bio/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/bio-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Business Segment

Income statement for 2026-01-01 through 2026-06-30. View: Business segment. Revenue and costs use their disclosed categories.

- **Net sales**: 1,243,100,000 US dollars
- **Cost of goods sold**: 587,900,000 US dollars
- **Gross profit**: 655,200,000 US dollars
- **Operating expenses (calculated)**: 548,500,000 US dollars
- **Segment profit (loss)**: 106,700,000 US dollars
- **Other income (expense), net (calculated)**: negative 254,400,000 US dollars
- **Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest**: negative 147,700,000 US dollars
- **(Provision) benefit for income taxes**: 8,000,000 US dollars
- **Net income attributable to Bio-Rad**: negative 155,700,000 US dollars
- **Life Science revenue**: 480,500,000 US dollars
- **Clinical Diagnostics revenue**: 762,600,000 US dollars
- **Life Science cost of revenue**: 209,400,000 US dollars
- **Clinical Diagnostics cost of revenue**: 378,500,000 US dollars
- **Selling, general and administrative expense**: 424,400,000 US dollars
- **Research and Development Expense**: 124,100,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/bio/fy2026-ytd-q2-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/bio-fy2026-ytd-q2-revenue-by-geography-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 1,243,100,000 US dollars
- **Cost of goods sold**: 587,900,000 US dollars
- **Gross profit**: 655,200,000 US dollars
- **Operating expenses (calculated)**: 548,500,000 US dollars
- **Segment profit (loss)**: 106,700,000 US dollars
- **Other income (expense), net (calculated)**: negative 254,400,000 US dollars
- **Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest**: negative 147,700,000 US dollars
- **(Provision) benefit for income taxes**: 8,000,000 US dollars
- **Net income attributable to Bio-Rad**: negative 155,700,000 US dollars
- **Europe**: 436,000,000 US dollars
- **Asia Pacific**: 232,200,000 US dollars
- **UNITED STATES**: 485,300,000 US dollars
- **Americas**: 89,600,000 US dollars
- **Selling, general and administrative expense**: 424,400,000 US dollars
- **Research and Development Expense**: 124,100,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.